These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
193 related articles for article (PubMed ID: 19918099)
1. Effects of HIV type-1 immune selection on susceptability to integrase inhibitor resistance. Tschochner M; Chopra A; Maiden TM; Ahmad IF; James I; Furrer H; Günthard HF; Mallal S; Rauch A; John M Antivir Ther; 2009; 14(7):953-64. PubMed ID: 19918099 [TBL] [Abstract][Full Text] [Related]
3. Molecular evolution of HIV-1 integrase during the 20 years prior to the first approval of integrase inhibitors. Meixenberger K; Yousef KP; Smith MR; Somogyi S; Fiedler S; Bartmeyer B; Hamouda O; Bannert N; von Kleist M; Kücherer C Virol J; 2017 Nov; 14(1):223. PubMed ID: 29137637 [TBL] [Abstract][Full Text] [Related]
4. Pol-Driven Replicative Capacity Impacts Disease Progression in HIV-1 Subtype C Infection. Ojwach DBA; MacMillan D; Reddy T; Novitsky V; Brumme ZL; Brockman MA; Ndung'u T; Mann JK J Virol; 2018 Oct; 92(19):. PubMed ID: 29997209 [TBL] [Abstract][Full Text] [Related]
5. Natural polymorphism of the HIV-1 integrase gene and mutations associated with integrase inhibitor resistance. Lataillade M; Chiarella J; Kozal MJ Antivir Ther; 2007; 12(4):563-70. PubMed ID: 17668566 [TBL] [Abstract][Full Text] [Related]
9. Genetic barrier to the development of resistance to integrase inhibitors in HIV-1 subtypes CRF01_AE and B. Nguyen HL; Ruxrungtham K; Delaugerre C Intervirology; 2012; 55(4):287-95. PubMed ID: 22456540 [TBL] [Abstract][Full Text] [Related]
10. Lack of primary mutations associated with integrase inhibitors among HIV-1 subtypes B, C, and F circulating in Brazil. Passaes CB; Guimarães ML; Fernandez SL; Lorete Rdos S; Teixeira SL; Fernandez JC; Morgado MG J Acquir Immune Defic Syndr; 2009 May; 51(1):7-12. PubMed ID: 19262402 [TBL] [Abstract][Full Text] [Related]
11. Circulating HIV-1 Integrase Genotypes in Tanzania: Implication on the Introduction of Integrase Inhibitors-Based Antiretroviral Therapy Regimen. Masoud S; Kamori D; Barabona G; Mahiti M; Sunguya B; Lyamuya E; Ueno T AIDS Res Hum Retroviruses; 2020 Jun; 36(6):539-543. PubMed ID: 32126792 [TBL] [Abstract][Full Text] [Related]
12. Natural polymorphisms of integrase among HIV type 1-infected South African patients. Fish MQ; Hewer R; Wallis CL; Venter WD; Stevens WS; Papathanasopoulos MA AIDS Res Hum Retroviruses; 2010 Apr; 26(4):489-93. PubMed ID: 20377427 [TBL] [Abstract][Full Text] [Related]
13. HIV-1 Integrase Diversity and Resistance-Associated Mutations and Polymorphisms Among Integrase Strand Transfer Inhibitor-Naive HIV-1 Patients from Cameroon. Mikasi SG; Gichana JO; Van der Walt C; Brado D; Obasa AE; Njenda D; Messembe M; Lyonga E; Assoumou O; Cloete R; Ikomey GM; Jacobs GB AIDS Res Hum Retroviruses; 2020 May; 36(5):450-455. PubMed ID: 31830799 [TBL] [Abstract][Full Text] [Related]
14. Absence of Integrase Strand Transfer Inhibitor Associated Resistance in Antiretroviral Therapy Naïve and Experienced Individuals from Western India. Karade S; Sen S; Sashindran VK AIDS Res Hum Retroviruses; 2019 Jun; 35(6):567-571. PubMed ID: 30793915 [TBL] [Abstract][Full Text] [Related]
15. Pre-treatment integrase inhibitor resistance is uncommon in antiretroviral therapy-naive individuals with HIV-1 subtype A1 and D infections in Uganda. McCluskey SM; Kamelian K; Musinguzi N; Kigozi S; Boum Y; Bwana MB; Muzoora C; Brumme ZL; Carrington M; Carlson J; Foley B; Hunt PW; Martin JN; Bangsberg DR; Harrigan PR; Siedner MJ; Haberer JE; Lee GQ AIDS; 2021 Jun; 35(7):1083-1089. PubMed ID: 33635845 [TBL] [Abstract][Full Text] [Related]
16. Integrase variability and susceptibility to HIV integrase inhibitors: impact of subtypes, antiretroviral experience and duration of HIV infection. Garrido C; Geretti AM; Zahonero N; Booth C; Strang A; Soriano V; De Mendoza C J Antimicrob Chemother; 2010 Feb; 65(2):320-6. PubMed ID: 20007331 [TBL] [Abstract][Full Text] [Related]
17. HIV-1 integrase polymorphisms are associated with prior antiretroviral drug exposure. van Hal SJ; Herring B; Deris Z; Wang B; Saksena NK; Dwyer DE Retrovirology; 2009 Feb; 6():12. PubMed ID: 19203393 [TBL] [Abstract][Full Text] [Related]
18. Prevalence of primary resistance mutations to integrase inhibitors in treatment-naïve and -experienced patients infected with B and non-B HIV-1 variants. Gutiérrez C; Hernández-Novoa B; Pérez-Elías MJ; Moreno AM; Holguín A; Dronda F; Casado JL; Moreno S HIV Clin Trials; 2013; 14(1):10-6. PubMed ID: 23372110 [TBL] [Abstract][Full Text] [Related]
19. Impact of the HIV-1 genetic background and HIV-1 population size on the evolution of raltegravir resistance. Fun A; Leitner T; Vandekerckhove L; Däumer M; Thielen A; Buchholz B; Hoepelman AIM; Gisolf EH; Schipper PJ; Wensing AMJ; Nijhuis M Retrovirology; 2018 Jan; 15(1):1. PubMed ID: 29304821 [TBL] [Abstract][Full Text] [Related]
20. HIV-1 acquired drug resistance to integrase inhibitors in a cohort of antiretroviral therapy multi-experienced Mexican patients failing to raltegravir: a cross-sectional study. Orta-Resendiz A; Rodriguez-Diaz RA; Angulo-Medina LA; Hernandez-Flores M; Soto-Ramirez LE AIDS Res Ther; 2020 Feb; 17(1):6. PubMed ID: 32041622 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]